NCT04481607

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.

Conditions

• Advanced Solid Tumor or Hematologic Tumor

Interventions

Type	Name	Description
DRUG	TQB3454	TQB3454 tablets is a small molecule oral drug.

Timeline

• Start date: 2020-08-24
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2020-07-22
• Last updated: 2022-01-10

Locations

5 sites across 1 country: China